Who
Brian Taylor Slingsby
Director
Company insider
Files Form 4 as: Director and 10% owner, Mineralys Therapeutics.
In numbers
- Trades disclosed
- 24
- Buys
- 2
- Sells
- 2
- Bought
- $7.5M
- Sold
- $13.2M
- Companies
- 1
- Companies where not an officer
- 1
- First trade
- 14 Feb 2023
- Last trade
- 22 Sep 2026
- Last filed
- 24 Sep 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 22 Sep 2026filed 24 Sep 2026 | MLYS Mineralys TherapeuticsBiotechnology | SEC FORM 4 Sold | $3.0M104,320 at $28.81 | filing |
| 22 Sep 2026filed 24 Sep 2026 | MLYS Mineralys TherapeuticsBiotechnology | SEC FORM 4 Sold | $3.0M104,320 at $28.81 | filing |
| 19 Feb 2026filed 20 Feb 2026 | MLYS Mineralys TherapeuticsBiotechnology | SEC FORM 4 Code A | —6,200 at $0.00 | filing |
| 19 Feb 2026filed 20 Feb 2026 | MLYS Mineralys TherapeuticsBiotechnology | SEC FORM 4 Code J | —6,200 at $0.00 | filing |
| 19 Feb 2026filed 20 Feb 2026 | MLYS Mineralys TherapeuticsBiotechnology | SEC FORM 4 Code J | —6,200 at $0.00 | filing |
| 19 Feb 2026filed 20 Feb 2026 | MLYS Mineralys Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —8,300 at $0.00 | filing |
| 19 Feb 2026filed 20 Feb 2026 | MLYS Mineralys Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code J | —8,300 at $0.00 | filing |
| 19 Feb 2026filed 20 Feb 2026 | MLYS Mineralys Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code J | —8,300 at $0.00 | filing |
| 19 Feb 2026filed 20 Feb 2026 | MLYS Mineralys Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —8,300 at $0.00 | filing |
| 19 Feb 2026filed 20 Feb 2026 | MLYS Mineralys Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code J | —8,300 at $0.00 | filing |
| 19 Feb 2026filed 20 Feb 2026 | MLYS Mineralys Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code J | —8,300 at $0.00 | filing |
| 19 Feb 2026filed 20 Feb 2026 | MLYS Mineralys TherapeuticsBiotechnology | SEC FORM 4 Code A | —6,200 at $0.00 | filing |
| 19 Feb 2026filed 20 Feb 2026 | MLYS Mineralys TherapeuticsBiotechnology | SEC FORM 4 Code J | —6,200 at $0.00 | filing |
| 19 Feb 2026filed 20 Feb 2026 | MLYS Mineralys TherapeuticsBiotechnology | SEC FORM 4 Code J | —6,200 at $0.00 | filing |
| 13 Mar 2025filed 25 Apr 2025 | MLYS Mineralys TherapeuticsBiotechnology | SEC FORM 4 Bought | $3.5M259,259 at $13.50 | filing |
| 24 Jul 2024filed 26 Jul 2024 | MLYS Mineralys TherapeuticsBiotechnology | SEC FORM 4 Sold | $7.2M550,000 at $13.05 | filing |
| 22 May 2024filed 7 Jan 2025 | MLYS Mineralys Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code J | —22,000 at $0.00 | filing |
| 22 May 2024filed 7 Jan 2025 | MLYS Mineralys Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code J | —22,000 at $0.00 | filing |
| 12 Jul 2023filed 14 Jul 2023 | MLYS Mineralys Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code J | —44,000 at $0.00 | filing |
| 12 Jul 2023filed 14 Jul 2023 | MLYS Mineralys Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code J | —88,000 at $0.00 | filing |
News
Mineralys Therapeutics Expands its Board of Directors with the Appointments of Kristine Peterson and Lonnel CoatsMLYS · manilatimes.net · 19 Oct 2026
0 headlines in the last 90 days name Brian Taylor Slingsby; 1 article from the last 14 days about the 1 company they traded most, at most three about any one of them.